Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 190 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Hepatitis b Clear all
Completed Phase 2 Interventional

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

NCT01309932
View directory record Official record
Conditions
Hepatitis C
Interventions
Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV)
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 25, 2026, 1:22 AM EDT
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen

NCT01204762
View directory record Official record
Conditions
Hepatitis B Virus
Interventions
pegIFN, pegIFNα-2a, PegIFN lambda, Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Anaheim, California • Garden Grove, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

NCT00507507
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Tenofovir DF, FTC, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 69 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

NCT04535544
View directory record Official record
Conditions
Hepatitis D, Chronic
Interventions
JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Redwood City, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

NCT04544956
View directory record Official record
Conditions
Hepatitis B
Interventions
GSK3228836, Nucleos(t)ide therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

NCT04629976
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
Drug
Lead sponsor
Nucorion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Monterey Park, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

NCT02979613
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
TAF, TDF, TAF Placebo, TDF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Pasadena, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2020 · Synced Oct 25, 2026, 1:22 AM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT04454567
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, Placebo, NrtI
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Pasadena, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 2Phase 3 Interventional

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

NCT03217422
View directory record Official record
Conditions
Autoimmune Hepatitis
Interventions
VAY736, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Coronado, California • Rialto, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

NCT04439539
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil, Tenofovir alafenamide, JNJ-56136379
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 4 Interventional

Long-Term Lamivudine Therapy for Chronic Hepatitis B

NCT00120354
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 25, 2026, 1:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment

NCT02364336
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 3 Interventional

A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Negative for Hepatitis B e Antigen

NCT00035789
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 25, 2026, 1:22 AM EDT
Completed No phase listed Observational

Epidemiological Study in Children and Adolescents With Chronic Hepatitis B

NCT01163240
View directory record Official record
Conditions
Liver Diseases, Hepatitis, Chronic, Hepatitis, Viral, Human, Hepatitis, Virus Diseases, Digestive System Diseases, Hepatitis B, Chronic, Hepatitis B, DNA Virus Infections
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years to 18 Years
Enrollment
1,640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 4 Interventional

Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

NCT00722332
View directory record Official record
Conditions
Hepatitis B, Liver Transplantation
Interventions
HepaGam B
Biological
Lead sponsor
Cangene Corporation
Industry
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
15
States / cities
Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 3 Interventional

A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

NCT00036608
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Entecavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Planet Hepatitis B

NCT04503993
View directory record Official record
Conditions
Hepatitis B
Interventions
Hepatitis B surface antigen, Hepatitis B core antibody, and Hepatitis B surface antibody
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 75 Years
Enrollment
5,004 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 25, 2026, 1:22 AM EDT
Recruiting Phase 1 Interventional

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

NCT04843852
View directory record Official record
Conditions
Hepatitis B, Chronic Hepatitis B
Interventions
Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).

NCT00435825
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
peginterferon alfa-2a [Pegasys]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
551 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Oct 25, 2026, 1:22 AM EDT
Withdrawn Phase 4 Interventional

Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks

NCT00862706
View directory record Official record
Conditions
Compensated Chronic Hepatitis B
Interventions
Telbivudine/LDT600A
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
16 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Bayside, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 25, 2026, 1:22 AM EDT
Completed No phase listed Observational

Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)

NCT05621304
View directory record Official record
Conditions
Chronic Hepatitis B Virus (Hbv)
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 25, 2026, 1:22 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

NCT03361956
View directory record Official record
Conditions
Hepatitis B
Interventions
JNJ-56136379, Placebo, NA (ETV or TDF)
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
18 Years to 70 Years
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Bakersfield, California • Orlando, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 25, 2026, 1:22 AM EDT